Cathie Wood didn't make a lot of moves on Thursday, but she certainly made them count. The CEO, co-founder, and ace stock picker for the Ark Investment family of exchange-traded funds (ETFs) loaded up on a market darling that sold off despite posting better-than-expected financial results. She also added to a pair of gene-targeting upstarts. 

Wood added to her stakes in CrowdStrike (NASDAQ: CRWD), Prime Medicine (NASDAQ: PRME), and Adaptive Biotechnologies (NASDAQ: ADPT) on Thursday. She publishes her transactions at the end of every trading day, making it easy to see what she's buying and selling. Let's take a closer look at her three purchases.

CrowdStrike came through with a "beat and raise" performance this week, but it wasn't enough. The provider of cloud-based security solutions for enterprises saw its revenue climb 42% to hit $692.6 million in its latest quarter, matching its 42% increase in annual recurring revenue. Analysts were only holding out for a 39% top-line growth spurt. 

Continue reading

Source Fool.com